NZ609803A - A2a antagonists as cognition and motor function enhancers - Google Patents
A2a antagonists as cognition and motor function enhancersInfo
- Publication number
- NZ609803A NZ609803A NZ609803A NZ60980311A NZ609803A NZ 609803 A NZ609803 A NZ 609803A NZ 609803 A NZ609803 A NZ 609803A NZ 60980311 A NZ60980311 A NZ 60980311A NZ 609803 A NZ609803 A NZ 609803A
- Authority
- NZ
- New Zealand
- Prior art keywords
- cognition
- antagonists
- preferred
- dopamine
- motor function
- Prior art date
Links
- 230000019771 cognition Effects 0.000 title abstract 2
- 239000005557 antagonist Substances 0.000 title 1
- 239000003623 enhancer Substances 0.000 title 1
- 230000007659 motor function Effects 0.000 title 1
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 abstract 4
- 229940123702 Adenosine A2a receptor antagonist Drugs 0.000 abstract 2
- XNBRWUQWSKXMPW-UHFFFAOYSA-N Tozadenant Chemical group C1=2SC(NC(=O)N3CCC(C)(O)CC3)=NC=2C(OC)=CC=C1N1CCOCC1 XNBRWUQWSKXMPW-UHFFFAOYSA-N 0.000 abstract 2
- 239000002467 adenosine A2a receptor antagonist Substances 0.000 abstract 2
- 229960003638 dopamine Drugs 0.000 abstract 2
- 239000002243 precursor Substances 0.000 abstract 2
- KORNTPPJEAJQIU-KJXAQDMKSA-N Cabaser Chemical compound C1=CC([C@H]2C[C@H](CN(CC=C)[C@@H]2C2)C(=O)N(CCCN(C)C)C(=O)NCC)=C3C2=CNC3=C1 KORNTPPJEAJQIU-KJXAQDMKSA-N 0.000 abstract 1
- 229940098778 Dopamine receptor agonist Drugs 0.000 abstract 1
- 229940121891 Dopamine receptor antagonist Drugs 0.000 abstract 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical group OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 abstract 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 208000027089 Parkinsonian disease Diseases 0.000 abstract 1
- 206010034010 Parkinsonism Diseases 0.000 abstract 1
- 229960004046 apomorphine Drugs 0.000 abstract 1
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 abstract 1
- 229960002802 bromocriptine Drugs 0.000 abstract 1
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 abstract 1
- 229960004596 cabergoline Drugs 0.000 abstract 1
- 230000007278 cognition impairment Effects 0.000 abstract 1
- 230000007423 decrease Effects 0.000 abstract 1
- 239000003210 dopamine receptor blocking agent Substances 0.000 abstract 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 229960004502 levodopa Drugs 0.000 abstract 1
- 229960003089 pramipexole Drugs 0.000 abstract 1
- FASDKYOPVNHBLU-ZETCQYMHSA-N pramipexole Chemical compound C1[C@@H](NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-ZETCQYMHSA-N 0.000 abstract 1
- 229960001879 ropinirole Drugs 0.000 abstract 1
- UHSKFQJFRQCDBE-UHFFFAOYSA-N ropinirole Chemical compound CCCN(CCC)CCC1=CC=CC2=C1CC(=O)N2 UHSKFQJFRQCDBE-UHFFFAOYSA-N 0.000 abstract 1
- 229960003179 rotigotine Drugs 0.000 abstract 1
- KFQYTPMOWPVWEJ-INIZCTEOSA-N rotigotine Chemical compound CCCN([C@@H]1CC2=CC=CC(O)=C2CC1)CCC1=CC=CS1 KFQYTPMOWPVWEJ-INIZCTEOSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2010/055681 WO2012060844A1 (en) | 2010-11-05 | 2010-11-05 | A2a antagonists as cognition and motor function enhancers |
| PCT/US2011/059466 WO2012061787A1 (en) | 2010-11-05 | 2011-11-04 | A2a antagonists as cognition and motor function enhancers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ609803A true NZ609803A (en) | 2016-08-26 |
Family
ID=46024745
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ609803A NZ609803A (en) | 2010-11-05 | 2011-11-04 | A2a antagonists as cognition and motor function enhancers |
| NZ746118A NZ746118A (en) | 2010-11-05 | 2011-11-04 | A2a antagonists as cognition and motor function enhancers |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ746118A NZ746118A (en) | 2010-11-05 | 2011-11-04 | A2a antagonists as cognition and motor function enhancers |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20130317019A1 (enExample) |
| EP (1) | EP2635256B1 (enExample) |
| JP (3) | JP6315991B2 (enExample) |
| KR (2) | KR102166229B1 (enExample) |
| CN (3) | CN103429221A (enExample) |
| AU (3) | AU2011323152A1 (enExample) |
| BR (1) | BR112013011068A2 (enExample) |
| CA (1) | CA2816834A1 (enExample) |
| EA (2) | EA035900B1 (enExample) |
| ES (1) | ES2842968T3 (enExample) |
| HK (1) | HK1245138A1 (enExample) |
| IL (2) | IL225868B (enExample) |
| MX (2) | MX2013005014A (enExample) |
| NZ (2) | NZ609803A (enExample) |
| WO (2) | WO2012060844A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6339758B2 (ja) * | 2012-07-02 | 2018-06-06 | 国立研究開発法人国立長寿医療研究センター | 軽度認知機能障害の有無の診断システム、認知機能検査用端末及び認知機能検査用プログラム |
| JO3544B1 (ar) | 2015-03-19 | 2020-07-05 | Kyowa Kirin Co Ltd | عامل علاجي للاختلال الوظيفي في الفص الجبهي |
| US10653699B2 (en) | 2015-06-19 | 2020-05-19 | Biotie Therapies, Inc. | Controlled-release tozadenant formulations |
| PT3445351T (pt) * | 2016-04-19 | 2024-11-14 | Intrabio Ltd | Acetil-leucina ou um sal farmaceuticamente aceitável seu derivado para melhoria da mobilidade |
| US11246871B2 (en) | 2016-07-15 | 2022-02-15 | Northwestern University | Targeting adenosine A2A receptors for the treatment of levodopa-induced dyskinesias |
| WO2018059531A1 (zh) * | 2016-09-30 | 2018-04-05 | 苏州晶云药物科技有限公司 | 一种腺苷a2a受体拮抗剂药物的晶型及其制备方法和用途 |
| WO2020146795A1 (en) | 2019-01-11 | 2020-07-16 | Omeros Corporation | Methods and compositions for treating cancer |
| EP4069239A4 (en) * | 2019-12-02 | 2023-11-29 | Sinopia Biosciences, Inc. | Treating cognitive disorders using trapidil |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2716404T3 (es) * | 2002-01-28 | 2019-06-12 | Kyowa Hakko Kogyo Kk | Antagonistas de receptores A2A para su uso en el tratamiento de trastornos del movimiento |
| AU2005247567B2 (en) * | 2004-05-24 | 2010-09-02 | F. Hoffmann-La Roche Ag | 4-hydroxy-4-methyl-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide |
| US7576073B2 (en) * | 2004-05-28 | 2009-08-18 | UNIVERSITé LAVAL | Combined therapy for the treatment of parkinson's disease |
| US8168785B2 (en) * | 2009-06-17 | 2012-05-01 | Biotie Therapies, Inc. | Benzothiazole derivatives |
-
2010
- 2010-11-05 WO PCT/US2010/055681 patent/WO2012060844A1/en not_active Ceased
-
2011
- 2011-11-04 MX MX2013005014A patent/MX2013005014A/es unknown
- 2011-11-04 EP EP11838922.0A patent/EP2635256B1/en active Active
- 2011-11-04 KR KR1020197005483A patent/KR102166229B1/ko not_active Expired - Fee Related
- 2011-11-04 CA CA2816834A patent/CA2816834A1/en not_active Abandoned
- 2011-11-04 US US13/882,132 patent/US20130317019A1/en not_active Abandoned
- 2011-11-04 CN CN2011800534450A patent/CN103429221A/zh active Pending
- 2011-11-04 CN CN201710583855.5A patent/CN107281491A/zh active Pending
- 2011-11-04 EA EA201390653A patent/EA035900B1/ru not_active IP Right Cessation
- 2011-11-04 BR BR112013011068A patent/BR112013011068A2/pt not_active IP Right Cessation
- 2011-11-04 KR KR1020137014385A patent/KR101955045B1/ko not_active Expired - Fee Related
- 2011-11-04 NZ NZ609803A patent/NZ609803A/en not_active IP Right Cessation
- 2011-11-04 JP JP2013537896A patent/JP6315991B2/ja not_active Expired - Fee Related
- 2011-11-04 AU AU2011323152A patent/AU2011323152A1/en not_active Abandoned
- 2011-11-04 MX MX2017009051A patent/MX382823B/es unknown
- 2011-11-04 WO PCT/US2011/059466 patent/WO2012061787A1/en not_active Ceased
- 2011-11-04 NZ NZ746118A patent/NZ746118A/en not_active IP Right Cessation
- 2011-11-04 ES ES11838922T patent/ES2842968T3/es active Active
- 2011-11-04 CN CN201811049033.XA patent/CN109223799A/zh active Pending
- 2011-11-04 EA EA202091356A patent/EA202091356A1/ru unknown
-
2013
- 2013-04-21 IL IL225868A patent/IL225868B/en active IP Right Grant
-
2016
- 2016-08-25 JP JP2016164379A patent/JP6444951B2/ja not_active Expired - Fee Related
-
2017
- 2017-03-02 AU AU2017201446A patent/AU2017201446A1/en not_active Abandoned
-
2018
- 2018-04-13 HK HK18104835.1A patent/HK1245138A1/zh unknown
- 2018-11-28 JP JP2018221977A patent/JP6611896B2/ja not_active Expired - Fee Related
- 2018-12-28 AU AU2018286608A patent/AU2018286608B2/en not_active Ceased
-
2019
- 2019-04-29 IL IL266321A patent/IL266321A/en unknown
-
2021
- 2021-06-07 US US17/341,106 patent/US20220125772A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ746118A (en) | A2a antagonists as cognition and motor function enhancers | |
| IL214501A0 (en) | Histamine h3 inverse agonists and antagonists and methods of use thereof | |
| EA201200507A1 (ru) | Применение активаторов никотинового ацетилхолинового рецептора альфа 7 | |
| ZA201105323B (en) | Agonists and antagonists of the sip5 receptor,and methods of uses thereof | |
| MY151568A (en) | Cyclohexyl amide derivatives and their use as crf-1 receptor antagonists | |
| IL216802A0 (en) | Histamine h3 inverse agonists and antagonists and methods of use thereof | |
| SV2010003642A (es) | Compuestos | |
| HUE036216T2 (hu) | Muszkarin receptor antagonista és béta-2-adrenoreceptor agonista kombinációi | |
| NZ615091A (en) | Treatment of portal hypertension and restoration of liver function using l-ornithine phenylacetate | |
| MX339878B (es) | Nuevas formas solidas de clorhidrato de bendamustina. | |
| CY1121081T1 (el) | Samidorphan (alks 33) σε συνδυασμο με βουπρενορφινη για την θεραπεια καταθλιπτικων διαταραχων | |
| DK2569308T3 (da) | Nye cyclohexylaminderivater med 2-adrenerge agonist- og m3-muskarin antagonistaktiviteter | |
| IL213096A0 (en) | Use of dr6 and p75 antagonists to promote survival of cells of the nervous system | |
| BR112012031361A2 (pt) | determinação de uma indicação de um valor de referência do consumo de serviço de abastecimento público | |
| ZA201301231B (en) | Treatment of l-dopa,dopamine agonist and/or dopamine enhancer induced disorders | |
| EP2593541A4 (en) | METHOD FOR THE TREATMENT OF HEPATORENAL SYNDROME AND HEPATIC ENZEPHALOPATHY WITH THROMBOXANE A2 RECEPTOR ANTAGONISTS | |
| TWD138601S1 (zh) | 戒指 | |
| UA110511C2 (ru) | Графітизований катодний блок зі зносостійкою поверхнею | |
| NZ729564A (en) | A2a antagonists as cognition and motor function enhancers | |
| IT1400311B1 (it) | Associazione di inibitori della xantina ossidasi e antagonisti del recettore dell'angiotensina ii e loro uso. | |
| PT2349352E (pt) | Utilização de 7-cloro-n,n,5-trimetil-4-oxo-3-fenil-3,5-dihidro- 4h-piridazino[4,5-b]indol-1-acetamida como um biomarcador de níveis de receptores periféricos de benzodiazepina | |
| JP2011112629A5 (enExample) | ||
| MX363662B (es) | Métodos para incrementar la sensibilidad a insulina mediante agonistas de receptores serotonérgicos 5-ht2. | |
| TWD143140S1 (zh) | 可調節板手 | |
| ZA201105874B (en) | Histamine h3 inverse agonists and antagonists and methods of use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 04 NOV 2018 BY AJ PARK Effective date: 20170322 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 04 NOV 2019 BY CPA GLOBAL Effective date: 20180920 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 04 NOV 2020 BY CPA GLOBAL Effective date: 20191121 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 04 NOV 2021 BY CPA GLOBAL Effective date: 20200917 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 04 NOV 2022 BY CPA GLOBAL Effective date: 20210924 |
|
| LAPS | Patent lapsed |